{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-005697","form_type":"8-K","ticker":"AEMD","cik":"0000882291","company_name":"AETHLON MEDICAL INC","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.144353+00:00","generated_at":"2026-05-31T09:32:24.716530+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aethlon Medical Q1 net loss $2.6M; cash $9.1M; ethics approvals for Hemopurifier trial","bullets":["Net loss $2.6M vs $3.3M YoY; operating expenses down 24% to $2.6M.","Cash balance $9.1M as of June 30, 2024.","Ethics approvals granted for Hemopurifier safety study in solid tumor patients on anti-PD-1 therapy.","Expects to open patient enrollment in October 2024; additional sites anticipated by end of 2024.","COVID-19 trial in India remains open; one patient treated to date."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-005697","json":"https://secwatch.observer/filing/0001683168-24-005697.json","markdown":"https://secwatch.observer/filing/0001683168-24-005697.md","text":"https://secwatch.observer/filing/0001683168-24-005697.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882291/000168316824005697/0001683168-24-005697-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882291/000168316824005697/aethlon_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:32:24.716530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}